Pacira BioSciences, Inc.

Pacira BioSciences develops and commercializes non-opioid pain management and regenerative health solutions for healthcare practitioners in the United States. The company's primary product is EXPAREL, a bupivacaine liposome injectable suspension used for postsurgical pain management. The company also markets ZILRETTA, a triamcinolone acetonide extended-release injectable suspension for osteoarthritis and knee pain management, and the iovera system, a handheld cryoanalgesia device that delivers controlled cold temperature to targeted peripheral nerves to interrupt pain signals. Additionally, Pacira is developing PCRX-201, a gene therapy vector platform designed for local administration of genetic medicines targeting conditions such as osteoarthritis.

The company maintains a development and commercialization agreement with Aratana Therapeutics for NOCITA, a bupivacaine liposome injectable suspension product for veterinary use. Pacira's revenue streams are generated primarily through sales of EXPAREL and ZILRETTA to healthcare providers, supplemented by the emerging iovera device franchise. The company was incorporated in Delaware in 2006 and rebranded from Pacira Pharmaceuticals to Pacira BioSciences in 2019. Pacira is headquartered in Brisbane, California and operates with a market capitalization of approximately $0.9 billion.